Suppliers / Zhejiang Apeloa Jiayuan Pharmaceutical

Zhejiang Apeloa Jiayuan Pharmaceutical

China Updated 9 July 2026

Zhejiang Apeloa Jiayuan Pharmaceutical is an API manufacturer based in China. It holds 22 active US drug master files and 7 valid CEPs across a filed portfolio of 19 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 11 April 2025 as NAI.

22
active US DMFs
7
valid CEPs
4
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
6 of 6 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 11 April 2025 NAI US FDA
  • 11 May 2018 NAI US FDA
  • 4 December 2015 VAI US FDA
  • 16 May 2014 VAI US FDA
  • 11 May 2012 VAI US FDA
  • 22 January 2009 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Dongyang City, China Not on file
Dongyang, China Not on file
Hengdian, China Not on file
China, China 3004944662

What they file, and where

Molecule Regulators Docs
Metoprolol EDQM, US FDA 4
Clopidogrel EDQM, US FDA 3
Bupropion US FDA 2
Irbesartan SFDA (Saudi Arabia), US FDA 2
Levetiracetam EDQM, US FDA 2
Quetiapine EDQM, US FDA 2
Sacubitril US FDA 2
Telmisartan SFDA (Saudi Arabia), US FDA 2
Venlafaxine EDQM, US FDA 2
Brivaracetam US FDA 1
Show all 19 molecules on file
Desvenlafaxine US FDA 1
Gabapentin US FDA 1
Iron Dextran US FDA 1
Laropiprant US FDA 1
Levosalbutamol US FDA 1
Metaxalone US FDA 1
Methocarbamol US FDA 1
Pregabalin US FDA 1
Sitagliptin US FDA 1

Also appears on these molecule pages

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA None 1

Comparing suppliers?

Choose your molecules and target markets. Zhejiang Apeloa Jiayuan Pharmaceutical comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was NAI, on 11 April 2025.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates